Revolution Medicines, Inc. (RVMD)
| Market Cap | 44.56B +526.6% |
| Revenue (ttm) | n/a |
| Net Income | -1.77B |
| EPS | -8.92 |
| Shares Out | 214.34M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,005,966 |
| Open | 221.50 |
| Previous Close | 221.15 |
| Day's Range | 205.82 - 221.50 |
| 52-Week Range | 37.56 - 224.31 |
| Beta | 1.40 |
| Analysts | Strong Buy |
| Price Target | 247.11 (+18.87%) |
| Earnings Date | Aug 5, 2026 |
About RVMD
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236)... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 22 analysts, the average rating for RVMD stock is "Strong Buy." The 12-month stock price target is $247.11, which is an increase of 18.87% from the latest price.
News
Revolution Medicines price target raised to $265 from $220 at UBS
UBS raised the firm’s price target on Revolution Medicines (RVMD) to $265 from $220 and keeps a Buy rating on the shares.
Revolution Medicines price target raised to $275 from $240 at Guggenheim
Guggenheim raised the firm’s price target on Revolution Medicines (RVMD) to $275 from $240 and keeps a Buy rating on the shares. Following early FDA approval of daraxonrasib, now named…
Why the Drugmaker Behind a Pancreatic Cancer Breakthrough Stayed Independent
Revolution Medicines attracted takeover interest but decided to go it alone. This week's FDA approval of its pancreatic cancer pill is the payoff.
Revolution Medicines Stock (RVMD) Gets Price Target Hike on New Revenue-Generating Cancer Drug
Shares in oncology drugs group Revolution Medicines ($RVMD) were healthier again today after a leading analyst said its new pancreatic cancer drug would be a revenue generator. In a note,…
Revolution Medicines price target raised to $246 from $227 at JPMorgan
JPMorgan raised the firm’s price target on Revolution Medicines (RVMD) to $246 from $227 and keeps an Overweight rating on the shares following the approval of Rasonque. Published first on…
Revolution Medicines price target raised to $251 from $203 at RBC Capital
RBC Capital analyst Leonid Timashev raised the firm’s price target on Revolution Medicines (RVMD) to $251 from $203 and keeps an Outperform rating on the shares. Despite the muted move,…
Revolution Medicines price target raised to $248 from $230 at Raymond James
Raymond James analyst Sean McCutcheon raised the firm’s price target on Revolution Medicines (RVMD) to $248 from $230 and keeps a Strong Buy rating on the shares. Rasonque’s earlier-than-expected FDA…
Revolution Medicines price target raised to $260 from $230 at Oppenheimer
Oppenheimer raised the firm’s price target on Revolution Medicines (RVMD) to $260 from $230 and keeps an Outperform rating on the shares. The firm views the FDA approval of RASONQUE…
Revolution Medicines price target raised to $320 from $230 at Evercore ISI
Evercore ISI raised the firm’s price target on Revolution Medicines (RVMD) to $320 from $230 and keeps an Outperform rating on the shares. The firm updated its model following the…
Revolution Medicines price target raised to $280 from $195 at H.C. Wainwright
H.C. Wainwright analyst Robert Burns raised the firm’s price target on Revolution Medicines (RVMD) to $280 from $195 and keeps a Buy rating on the shares following the FDA approval…
Revolution Medicines prices Rasonque at $39,800 for 30-day supply
Revolution Medicines (RVMD) disclosed that following FDA approval of Rasonque for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemi...
Revolution Medicines Transcript: FDA announcement
FDA approved RASONQUE (daraxonrasib) as the first targeted therapy for metastatic pancreatic cancer, based on phase III data showing a 60% reduction in risk of death and improved quality of life. The drug is available immediately in the U.S., with robust commercialization and patient support in place.
Revolution Medicines Slides: FDA announcement
Revolution Medicines has posted slides in relation to its latest quarterly earnings report, which was published on August 26, 2026.
Revolution Medicines Press release: FDA announcement
Revolution Medicines issued a press release on August 26, 2026, disclosing material business information to investors.
Revolution Medicines announces FDA approval of Rasonque in adults
Revolution Medicines (RVMD) announced that the U.S. Food and Drug Administration has approved RASONQUE once-daily oral tablets, for the treatment of adults with metastatic pancreatic adenocarcinoma wh...
U.S. FDA Approves Revolution Medicines' RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
This release contains multimedia assets available for download here
Revolution Medicines Stock (RVMD) Boosted By FDA Pancreatic Cancer Approval
Shares in oncology drugs group Revolution Medicines ($RVMD) were higher today after the U.S. Food and Drug Administration approved its treatment for advanced pancreatic cancer. The FDA said it had…
Revolution Medicines Wins FDA Approval for Pancreatic Cancer Pill. What It Means for the Stock.
Daraxonrasib, the pill touted by a former member of Congress and cancer patient as a ‘miracle drug,' has been granted approval in patients with pancreatic adenocarcinoma.
The FDA approved a new drug from Revolution Medicines that promises to transform treatment of pancreatic cancers that kill many patients within a year of diagnosis
The FDA approved a therapy from Revolution Medicines that slows a cancer that kills 7 of out 8 patients within five years.
Revolution Medicines gets FDA nod for targeted pancreatic cancer drug
The U.S. Food and Drug Administration on Wednesday approved Revolution Medicines' targeted drug for adults with metastatic pancreatic cancer who have received prior treatment or cannot receive com...
Revolution Medicines price target raised to $179 from $151 at Bernstein
Bernstein analyst Jeffrey Walch raised the firm’s price target on Revolution Medicines (RVMD) to $179 from $151 and keeps a Market Perform rating on the shares. The firm is bullish…
Revolution Medicines price target raised to $231 from $210 at Truist
Truist raised the firm’s price target on Revolution Medicines (RVMD) to $231 from $210 and keeps a Buy rating on the shares. The firm is increasing its estimates to reflect…
Revolution Medicines price target raised to $220 from $165 at Wolfe Research
Wolfe Research analyst Kalpit Patel raised the firm’s price target on Revolution Medicines (RVMD) to $220 from $165 and keeps an Outperform rating on the shares. Given “good progress” on…
BeOne Medicines partners with Revolution Medicines for clinical development
BeOne Medicines (ONC) and Revolution Medicines (RVMD) announced a multi-part collaboration including: a clinical collaboration to evaluate drug combinations incorporating select clinical-stage oncolog...
BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration
SAN CARLOS, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, and Revolution Medicines, Inc. (Nas...